問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

China Medical University Hospital

List

1858Cases

2018-01-29 - 2023-06-20

Others

A Phase 3 Randomized Double-Blind Placebo-Controlled Study Investigating the Efficacy and Safety of Roxadustat (FG-4592) for Treatment of Anemia in Patients with Lower Risk Myelodysplastic Syndrome (MDS) with Low Red Blood Cell (RBC) Transfusion Burden (LTB)

  • Condition/Disease

    anemia

  • Test Drug

    FG-4592

Participate Sites
2Sites

Terminated2Sites

2017-06-30 - 2022-07-29

Phase III

A randomized, double-blind, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy and safety of adjunctive Brivaracetam in subjects (≥16 to 80 years of age) with partial seizures with or without secondary generalization

  • Condition/Disease

    adjunctive treatment in subjects (>=16 to 80 years of age) with ​partial seizures with or without secondary generalization

  • Test Drug

    BRIVARACETAM®, tablets for oral administration

Participate Sites
6Sites

Recruiting1Sites

Terminated5Sites

2022-04-01 - 2024-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Not yet recruiting2Sites

Recruiting3Sites

2021-10-01 - 2022-04-26

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Not yet recruiting7Sites

2021-11-01 - 2027-09-01

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2022-02-01 - 2025-12-01

Phase II/III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Not yet recruiting4Sites

2023-09-01 - 2026-06-30

Phase III

A Phase 3/3b, Randomized, Observer-blind, Multicenter Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Quadrivalent Influenza Vaccine in Adults ≥65 Years of Age

  • Condition/Disease

    Influenza, Human

  • Test Drug

    Fluad Tetra

Participate Sites
5Sites

Not yet recruiting4Sites

Recruiting1Sites

2018-11-01 - 2022-06-21

Phase III

A Randomized, Double-Blind, Placebo-Controlled Confirmatory Study of the Safety and Efficacy of ASP015K in Patients with Rheumatoid Arthritis (RA) who Had an Inadequate Response or Intolerance to MTX

  • Condition/Disease

    Rheumatoid Arthritis (RA)

  • Test Drug

    ASP015K

Participate Sites
6Sites

Terminated5Sites

黃春明
China Medical University Hospital-Taipei

未分科

張棋楨
Taipei Medical University Hospital

2018-07-01 - 2021-12-31

Phase III

A Phase III, Randomized, Placebo Controlled, Multicenter, Double-Blind Study Comparing Toripalimab Injection (JS001) Combined With Chemotherapy Versus Placebo Combined With Chemotherapy for Recurrent or Metastatic Nasopharyngeal Cancer

  • Condition/Disease

    Nasopharyngeal Cancer

  • Test Drug

    JS001

Participate Sites
8Sites

Terminated7Sites

王宏銘
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

楊慕華
Taipei Veterans General Hospital

Division of Hematology & Oncology

2018-07-30 - 2020-09-30

Phase III

A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of IMAB362 Plus mFOLFOX6 Compared with Placebo Plus mFOLFOX6 as First-line Treatment of Subjects with Claudin (CLDN)18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

  • Condition/Disease

    Claudin (CLDN)18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

  • Test Drug

    IMAB362

Participate Sites
9Sites

Recruiting6Sites

Terminated2Sites

陳仁熙
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

洪逸平
Taipei Veterans General Hospital

Division of Hematology & Oncology

1 149 150 151 152 153 186
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB